Oritavancin: A New Lipoglycopeptide Antibiotic in the Treatment of Gram-Positive Infections

Infectious Diseases and Therapy
Karrine D BradeMichael J Rybak

Abstract

Resistance among Gram-positive organisms has been steadily increasing over the last several years; however, the development of new antibiotics to treat infections caused from these organisms has fallen short of the emergent need. Specifically, resistance among Staphylococcus aureus and Enterococcus spp. to essential antibiotics is considered a major problem. Oritavancin is a semisynthetic lipoglycopeptide antibiotic that was recently approved for the treatment of acute bacterial skin and skin structure infections (ABSSSI). While structurally related to vancomycin, oritavancin also possesses unique mechanisms of action that greatly enhance its antimicrobial potency against multi-drug resistant pathogens including both VanA- and VanB-mediated vancomycin-resistant enterococci. Owing to the addition of the highly hydrophobic tail group, oritavancin possesses a prolonged half-life ranging from 200-300 h. Although oritavancin is only currently Food and Drug Administration approved for ABSSSI, this agent may eventually play a role in additional indications where new innovative therapy is needed including bacteremia and deep-seeded, Gram-positive infections such as infective endocarditis or osteomyelitis. This review will focus on orit...Continue Reading

References

Jun 1, 1996·The Journal of Antibiotics·R D CooperR C Thompson
Oct 1, 1996·Antimicrobial Agents and Chemotherapy·M BaptistaM Arthur
Oct 23, 1997·Antimicrobial Agents and Chemotherapy·F BiavascoP E Varaldo
Apr 29, 1998·Antimicrobial Agents and Chemotherapy·G W KaatzM J Rybak
Apr 24, 2003·Antimicrobial Agents and Chemotherapy·Carole J BoylanThomas R Parr
Oct 12, 2004·Diagnostic Microbiology and Infectious Disease·Sujata M BhavnaniPaul G Ambrose
Feb 9, 2008·Journal of Molecular Biology·Sung Joon KimJacob Schaefer
Jul 9, 2008·The Journal of Antimicrobial Chemotherapy·Rachael O'ConnorMark H Wilcox
Dec 24, 2008·Antimicrobial Agents and Chemotherapy·Adam BelleyGregory Moeck
Jun 23, 2009·Journal of Molecular Biology·Sung Joon KimJacob Schaefer
Jul 7, 2009·Journal of Molecular Biology·Gary J PattiJacob Schaefer
May 4, 2011·Antimicrobial Agents and Chemotherapy·Lala M DunbarUNKNOWN SIMPLIFI Study Team
Aug 18, 2012·The Journal of Antimicrobial Chemotherapy·Jane FreemanMark H Wilcox
Dec 12, 2012·Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America·Dawn M SievertUNKNOWN National Healthcare Safety Network (NHSN) Team and Participating NHSN Facilities
Jun 14, 2013·The Journal of Antimicrobial Chemotherapy·C H ChiltonM H Wilcox
Dec 24, 2013·Diagnostic Microbiology and Infectious Disease·John EdelsbergDavid J Weber
Jun 5, 2014·The New England Journal of Medicine·G Ralph CoreyUNKNOWN SOLO I Investigators
Oct 9, 2014·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·G Ralph CoreyUNKNOWN SOLO II Investigators
Aug 5, 2015·Antimicrobial Agents and Chemotherapy·Dario LehouxThomas R Parr

❮ Previous
Next ❯

Citations

Sep 24, 2016·Pharmaceuticals·Nermina Malanovic, Karl Lohner
Jan 25, 2017·Current Opinion in Infectious Diseases·Mordechai Grupper, David P Nicolau
Apr 5, 2018·Expert Review of Anti-infective Therapy·Ayesha KhanCesar A Arias
Jun 22, 2018·Current Reviews in Musculoskeletal Medicine·Mariam TahaAlberto V Carli
Sep 29, 2018·Surgical Infections·Donald E Fry
Oct 27, 2017·The Journal of Antibiotics·Yoshiaki Takahashi, Masayuki Igarashi
Apr 9, 2019·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Dee Shortridge, Robert K Flamm
Jul 10, 2019·Acta Parasitologica·Dejan LauševićSonja Obrenović
Nov 2, 2019·The Journal of Biological Chemistry·Edward MarschallJulien Tailhades
Jul 10, 2019·Open Forum Infectious Diseases·Taylor MorrisetteMartin Krsak
Nov 24, 2019·Probiotics and Antimicrobial Proteins·Ingvild S ReinsethDzung B Diep
Jun 27, 2020·Drugs -- Real World Outcomes·Warren E Rose, Paul R Hutson
Jul 10, 2018·Current Medicinal Chemistry·Ananda Kumar KonreddyYongseok Choi
Feb 26, 2019·Future Medicinal Chemistry·Catarina Dias, Amélia P Rauter
Jan 5, 2021·Current Opinion in Infectious Diseases·Daniele R GiacobbeMatteo Bassetti
Jan 7, 2021·Current Opinion in Infectious Diseases·Matteo BassettiDaniele R Giacobbe
Nov 6, 2018·Journal of the American Chemical Society·Alexandra AntonoplisLynette Cegelski
Jan 25, 2018·ACS Infectious Diseases·Mark A T BlaskovichMatthew A Cooper

❮ Previous
Next ❯

Clinical Trials Mentioned

NCT00514527
NCT01252719
NCT01252732
NCT02471690

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.